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was significant decrease in WBC (median 6.2 vs. 4.9 10^3/ul; 
p-0.03), PLT (235 vs. 184 10^3/ul; p-0.01) before and after 
radiotherapy. RBC and Hb did not significantly decrease. The 
maximum Grade 3 early skin toxicity by the end of treatment 
was present only in two patients. No Grade 4 toxicities were 
observed. The maximum Grade 2 fatigue, Grade 1 dysphagia, 
Grade 1 pain with swallowing were recorded. The early skin 
toxicity resolved in all patients evaluated one month after 
finishing the treatment. 
Conclusions: This 6-week course of definitive radiotherapy 
using SIB technique showed to be feasible and was associated 
with acceptable early skin toxicity. Long-term follow-up data 
are needed to assess late toxicity and clinical outcomes.  
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Purpose/Objective: to review data for patients with stage T4 
and/or M1 lym esophageal cancer who have been treated 
with definitive chemoradiotherapy since 2000 in an 
institution that is one of high volume centers in Japan. 
Materials and Methods: We retrospectively reviewed data for 
all patients with T4 and/or M1 lym esophageal cancer who 
had been treated by definitive chemoradiotherapy between 
2000 and 2013 in Tohoku University Hospital. The eligibility 
criteria included 1) histopathologically proven esophageal 
cancer, 2) T4 and/or M1 lymph (UICC 2002), 3) having 
undergone at least 1 cycle of concomitant chemotherapy, 4) 
having been irradiated with 50 or more Gy, and 5) no other 
active malignant tumor during treatment. Survival estimates 
were calculated from the first day of radiotherapy using the 
Kaplan-Meier method, and differences were evaluated by the 
log-rank test. Statistical significance was defined as a value 
of p<0.05 in the present study. SPSS software for Windows 
version 20.0 was used for all calculations. Toxicity was 
graded according to the Common Terminology Criteria for 
Adverse Events (CTCAE v3.0). 
Results: Data for 86 patients were used for analysis in this 
study. Median age of the patients was 66 years. Primary sites 
were in the cervical, upper thoracic, middle thoracic, lower 
thoracic and abdominal esophagus in 9 patients, 20 patients, 
49 patients, 7 patients and 1 patient, respectively. Clinical 
stages were III in 54 patients, IVa in 5 patients and IVb in 27 
patients. Median total irradiation dose was 60 Gy (range, 50-
70 Gy). CDDP+5-FU, CDGP+5-FU, CDDP+5-FU+DOC and 
CDGP+DOC were performed as concomitant chemotherapy 
with radiotherapy in 47, 35, 2 and 2 patients, respectively. 
Median observation period for the survivors was 36.1 months. 
At the last observation date, there were 68 deaths including 
5 intercurrent deaths. The 1-year and 3-year overall survival 
rates were 40.1% (95%CI=29.5-50.7%) and 22.4% (95%CI=13.0-
31.8%), respectively. Three patients had grade 3 radiation 
pneumonitis and 1 patient developed grade 5 radiation 
pneumonitis. One patient showed grade 3 pleural effusion. 
The overall survival of patients without M1 lym was 
significantly better than that of patients with Ml lym (3-y, 
32.3% (95%CI=19.0-45.6%) vs. 6.7% (95%CI=0-15.7%, p=0005). 
The overall survival in recent patients (2007-2013) was not 
improved from that in past patients (2000-2006) (3-y, 15.9% 
(95%CI=2.0-29.8%) vs. 26.0% (95%CI=13.8-38.2%), p=0.32). 
There was no significant difference of survival rate between 
patients treated with 60 Gy or less and patients treated with 
more than 60 Gy (3-y, 25.3% (95%CI=10.8-39.8%) vs. 20.0% 
(95%CI=7.8-32.2%), p=0.45). 
Conclusions: We showed the results of definitive 
chemoradiotherapy for T4 and/or M1 lym esophageal cancer 
in a Japanese high-volume center after 2000. T4 patients 
without M1 lym showed a relatively good 3-year survival rate 
of about 30%; however, the results were not improved after 
2000.  
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Purpose/Objective: The optimal waiting period between 
completion of neoadjuvant therapy and surgery in locally 
advanced rectal cancer (LARC) is controversial. The 
recommended duration and its impact in surgical radicality is 
discussed. The specific purpose of this study is to evaluate 
the effect of surgical interval on cancer response: tumor 
regression grade (TRG), postoperative morbidity and long-
term oncologic outcomes. 
Materials and Methods: Retrospective data analysis from 
patients with clinical stage II-III treated with chemoradiation 
(CRT) followed by surgery and IORT, between February 1995 
and December 2012 is reported. Two groups according to the 
interval between neoadjuvant therapy and surgery (< 6 and ≥ 
6 weeks) are evaluated. Clinico-pathological data related to 
response patterns as well as survival were compared. 
Results: Three hundred thirty-five patients were assessed, of 
which 59,4% underwent delayed surgery. Baseline 
characteristics of the study groups, showed a higher 
proportion of patients with increased oncologic risk factors in 
the delayed surgery group (cT4, 14,1% vs 18%; cN+, 64,1% vs 
76,6%). Complete pathological response (ypT0N0) and TRG 3-
4 categories incidence are not significantly different among 
groups (8,8% vs 12,1%, p = 0,348; 41% vs 50,8%, p = 0.082), 
respectively. The maximal dimension of residual tumor post-
neoadjuvant treatment was influenced by surgical period (p = 
0.006). Longer surgical interval did not affect incidence or 
severity of complications or length of hospital admission 
(9,50 vs 10 days; p = 0.093). After a median follow-up time of 
71 months, delayed surgery had a significant impact on 
overall survival (55,9% vs 70,4%; p = 0,014), not observed in 
disease-free survival (69,9% vs 74,9%; p = 0,233) or local 
relapse-free survival (LRFS) (90,4% vs 94,5%; p = 0,123). 
